FDA Approves Pembrolizumab for BCG-Unresponsive NMIBC

Bladder Cancer

Wright KM. Oncology (Williston Park) 2020.


The FDA approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.